HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Geminofloxacin for the management of community-acquired respiratory tract infections.

Abstract
Community-acquired lower respiratory tract infections (LRTIs) exert a growing clinical and financial burden on healthcare systems and employers. In addition, antimicrobial resistance among pathogens, such as Streptococcus pneumoniae, has compromised the use of commonly prescribed antimicrobial compounds. Newer fluoroquinolones have been developed to meet these emerging demands. Gemifloxacin is a potent, dual-acting fluoroquinolone with excellent activity against S. pneumoniae (MIC(90)0.03-0.06 microg/ml) including those strains demonstrating resistance to other classes of antibiotics. Gemifloxacin demonstrated excellent clinical success in community-acquired lower respiratory infections, has an acceptable safety profile, and is a cost-effective alternative in the management of LRTIs including those caused by resistant pathogens.
AuthorsJ M Blondeau, G Tillotson, J Deangelis
JournalJournal of chemotherapy (Florence, Italy) (J Chemother) Vol. 18 Issue 6 Pg. 582-8 (Dec 2006) ISSN: 1120-009X [Print] Italy
PMID17267335 (Publication Type: Journal Article, Review)
Chemical References
  • Anti-Bacterial Agents
  • Fluoroquinolones
  • Naphthyridines
  • gemifloxacin
Topics
  • Anti-Bacterial Agents (therapeutic use)
  • Community-Acquired Infections (drug therapy, economics, microbiology)
  • Cost-Benefit Analysis
  • Drug Resistance, Bacterial
  • Fluoroquinolones (therapeutic use)
  • Humans
  • Naphthyridines (therapeutic use)
  • Respiratory Tract Infections (drug therapy, economics, microbiology)
  • Streptococcus pneumoniae (drug effects)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: